Drug Safety

, Volume 29, Issue 10, pp 944–944 | Cite as

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

  • T. Roisin
  • A. Van Ermen
  • A. Rogiers
Abstracts

Keywords

Verapamil Diltiazem Dioxin Hypokalemia Cholinesterase Inhibitor 

References

  1. 1.
    Répertoire Commenté des Médicaments 2006/Gecommentarieerd Geneesmiddelenrepertorium 2006, edited by the Belgian Center for Pharmacotherapeutic Information (CBIP/BCFI)Google Scholar
  2. 2.
    Leentjes AFG, Kragten JA. Totaal atrioventriculair blok tijdens behandeling met galantamine. Ned Tijdschr Geneesk 2006; 150: 563–6Google Scholar
  3. 3.
    Anonymous. Maladie d’Alzheimer: gare aux interactions avec les anticholinestérasiques. La Revue Prescrire 2006; 26: 111–5Google Scholar
  4. 4.
    Anonymous. Effect indésirables cardiaques des inhibiteurs des cholinestérases/Cardiale ongewenste effecten van cholinesterase-inhibitoren. Folia Pharmacotherapeutica 2006; 33:54 (via http://www.cbip.be/http://www.bcfi.be)Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • T. Roisin
    • 1
  • A. Van Ermen
    • 2
  • A. Rogiers
    • 3
  1. 1.Vigilance departmentDirectorate-General for Medicinal Products (DGMP) Federal Public Service Health, Food Chain Safety and EnvironmentBrusselsBelgium
  2. 2.Belgian Centre for Pharmacotherapeutic Information (BCFI/CBIP)GentBelgium
  3. 3.Registration DepartmentDirectorate-General for Medicinal Products (DGMP), Federal Public Service Health, Food Chain Safety and EnvironmentBrusselsBelgium

Personalised recommendations